Xinhua Pharmaceutical (00719.HK, 000756.SZ) Secures Drug Registration Certificate for Alendronate Sodium Oral Solution

Bulletin Express

Oct 31

Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical) has obtained a Drug Registration Certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration. The product is classified as a prescription drug for treating osteoporosis, particularly in postmenopausal women to help prevent hip and spinal fractures, and in men to increase bone mass.

Alendronate Sodium Oral Solution is specified as 75ml:70mg (calculated based on C4H13NO7P2). In 2024, alendronate sodium products registered combined sales of nearly RMB 720 million across public hospitals, primary medical institutions, and retail pharmacies in China.

According to the announcement, Xinhua Pharmaceutical entered a technology development agreement in May 2024 with Shandong Langnuo Pharmaceutical Co., Ltd. to secure all rights and benefits to the product’s registration approval documents and related intellectual property upon the full settlement of relevant fees. The subsequent change of applicant was approved, making Xinhua Pharmaceutical the formal marketing license holder of this product. The company states that securing this certificate will further enrich its product portfolio.

The announcement highlights that sales performance may be affected by factors such as policy updates, market conditions, and bidding processes. Xinhua Pharmaceutical advises investors to pay close attention to potential risks and exercise caution.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106345081"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106345081\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106345081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106345081","market":"us","top_or_hot":-1,"title":"Xinhua Pharmaceutical (00719.HK, 000756.SZ) Secures Drug Registration Certificate for Alendronate Sodium Oral Solution","media":"Bulletin Express","content":"<p>Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical) has obtained a Drug Registration Certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration. The product is classified as a prescription drug for treating osteoporosis, particularly in postmenopausal women to help prevent hip and spinal fractures, and in men to increase bone mass.</p>\n<p>Alendronate Sodium Oral Solution is specified as 75ml:70mg (calculated based on C4H13NO7P2). In 2024, alendronate sodium products registered combined sales of nearly RMB 720 million across public hospitals, primary medical institutions, and retail pharmacies in China.</p>\n<p>According to the announcement, Xinhua Pharmaceutical entered a technology development agreement in May 2024 with Shandong Langnuo Pharmaceutical Co., Ltd. to secure all rights and benefits to the product’s registration approval documents and related intellectual property upon the full settlement of relevant fees. The subsequent change of applicant was approved, making Xinhua Pharmaceutical the formal marketing license holder of this product. The company states that securing this certificate will further enrich its product portfolio.</p>\n<p>The announcement highlights that sales performance may be affected by factors such as policy updates, market conditions, and bidding processes. Xinhua Pharmaceutical advises investors to pay close attention to potential risks and exercise caution.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xinhua Pharmaceutical (00719.HK, 000756.SZ) Secures Drug Registration Certificate for Alendronate Sodium Oral Solution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXinhua Pharmaceutical (00719.HK, 000756.SZ) Secures Drug Registration Certificate for Alendronate Sodium Oral Solution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-31 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical) has obtained a Drug Registration Certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration. The product is classified as a prescription drug for treating osteoporosis, particularly in postmenopausal women to help prevent hip and spinal fractures, and in men to increase bone mass.</p>\n<p>Alendronate Sodium Oral Solution is specified as 75ml:70mg (calculated based on C4H13NO7P2). In 2024, alendronate sodium products registered combined sales of nearly RMB 720 million across public hospitals, primary medical institutions, and retail pharmacies in China.</p>\n<p>According to the announcement, Xinhua Pharmaceutical entered a technology development agreement in May 2024 with Shandong Langnuo Pharmaceutical Co., Ltd. to secure all rights and benefits to the product’s registration approval documents and related intellectual property upon the full settlement of relevant fees. The subsequent change of applicant was approved, making Xinhua Pharmaceutical the formal marketing license holder of this product. The company states that securing this certificate will further enrich its product portfolio.</p>\n<p>The announcement highlights that sales performance may be affected by factors such as policy updates, market conditions, and bidding processes. Xinhua Pharmaceutical advises investors to pay close attention to potential risks and exercise caution.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山东新华制药股份","start_time":0,"source_url":"","article_id":"1106345081","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106345081","pubTimestamp":1761901408,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical) has obtained a Drug Registration Certificate for Alendronate Sodium Oral Solution from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份"},"translate_title":"新华制药（00719.HK，000756.SZ）阿仑膦酸钠口服溶液获药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical) has obtained a Drug Registration Certificate for Alendronate Sodium Oral Solution from the National Medical Products Administration. The product is classified as a prescription drug for treating osteoporosis, particularly in postmenopausal women to help prevent hip and spinal fractures, and in men to increase bone mass.\nAlendronate Sodium Oral Solution is specified as 75ml:70mg (calculated based on C4H13NO7P2). In 2024, alendronate sodium products registered combined sales of nearly RMB 720 million across public hospitals, primary medical institutions, and retail pharmacies in China.\nAccording to the announcement, Xinhua Pharmaceutical entered a technology development agreement in May 2024 with Shandong Langnuo Pharmaceutical Co., Ltd. to secure all rights and benefits to the product’s registration approval documents and related intellectual property upon the full settlement of relevant fees. The subsequent change of applicant was approved, making Xinhua Pharmaceutical the formal marketing license holder of this product. The company states that securing this certificate will further enrich its product portfolio.\nThe announcement highlights that sales performance may be affected by factors such as policy updates, market conditions, and bidding processes. Xinhua Pharmaceutical advises investors to pay close attention to potential risks and exercise caution.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}